You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
About 63 million votes were in favor of the deal, representing more than 72.5 percent of all outstanding Alere shares as of the May 31 record date.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
Sales for its cardiometabolic tests dropped sharply, while sales for its flu tests soared and its consumer diagnostics sales were flat.
The firm's Q4 global influenza sales were up 60 percent year over year, and in 2016 its global infectious disease business achieved double-digit sales growth.
Roche's Bluetooth-enabled meter gives patients the option to bypass frequent trips to the clinic in favor of doing anticoagulation testing at home.
This week's news includes Alere, Fulget Diagnostics, Trovagene, Great Basic Scientific, Interleukin, and Danaher.
Abbott CEO Miles White said that while Alere is a bit of a fixer upper, he is pleased to have a resolution to issues surrounding the proposed acquisition.
The firms also dropped their lawsuits against each other, and said they expect to complete the merger by the end of the third quarter.
The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
Researchers and companies move to develop blood-based tests for concussion, according to Scientific American.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.